Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications B cell lymphoma
- Focus Therapeutic Use
- 03 Jan 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.